Patent US1997467A successfully refreshed from Google Patents.
Patent US3419793A successfully refreshed from Google Patents.
Patent US4921697A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4921697A Expired / Lapsed US ⏱️ 0.0 years remaining

IFN-gamma as an active substance for inhibiting and preventing degradation processes in bone

Assignee: Boehringer Ingelheim International GmbH
•
Filing: 1986-05-30
•
Granted: 1990-05-01
•
Expires: 2006-05-30
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract This invention relates to methods for preventing and treating bone diseases caused by bone loss comprising administering to a patient a pharmaceutical composition with IFN-γ as the active substance.

Inventors

  • 👤 Meinrad Peterlik
  • 👤 Oskar Hoffmann

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-24 10:21
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/21; A61K38/217; A61P; A61P1/00; A61P1/02; A61P19/00; A61P19/08; A61P19/10; A61P3/00; A61P35/00; A61P43/00

Claims Analysis

Total Claims: 13
Claim 1
Independent Claim 34 words
A method for inhibiting, preventing, or controlling bone loss in a patient comprising administering a pharmaceutical composition to said patient comprising gamma-interferon in an amount effective to inhibit, prevent, or control said bone loss.
Claim 2
Independent Claim 34 words
A method for inhibiting, preventing, or controlling bone loss in a patient comprising administering a pharmaceutical composition to said patient comprising gamma-interferon in an amount effective to inhibit, prevent, or control said bone loss.
Claim 3
Dependent Claim 22 words
The method of claim 1 wherein said bone loss is a degenerative systemic or local bone loss of inflammatory or non-inflammatory origin.
Claim 4
Dependent Claim 20 words
The method of claim 1 wherein said bone loss is caused by local or generalized decomposition of the bone tissue.
Claim 5
Dependent Claim 14 words
The method of claim 1 wherein said bone loss is caused by pathological disease.
Claim 6
Dependent Claim 14 words
The method of claim 1 wherein said bone loss is a result of osteoporosis.
Claim 7
Dependent Claim 15 words
The method of claim 1 wherein said bone loss is a result of Paget's disease.
Claim 8
Dependent Claim 15 words
The method of claim 1 wherein said bone loss is the result of rheumatic arthritis.
Claim 9
Dependent Claim 17 words
The method, of claim 1 wherein said bone loss is the result of jaw and tooth diseases.
Claim 10
Dependent Claim 17 words
The method of claim 1 wherein said bone loss is the result of osteodystophies caused by parathormone.
Claim 11
Dependent Claim 17 words
The method of claim 1 wherein said bone loss is the result of hypercalcaemia in prostaglandinsynthesizing tumors.
Claim 12
Independent Claim 48 words
A method for inhibiting, preventing, or controlling bone loss is a patient comprising adminstering a pharmaceutical composition to said patient comprising gamma-interferon in an amount effective to inhibit, prevent, or control bone loss, in combination with calcitonin in an amount sufficient to inhibit, prevent, or control bone loss.
Claim 13
Independent Claim 48 words
A method for inhibiting, preventing, or controlling bone loss is a patient comprising adminstering a pharmaceutical composition to said patient comprising gamma-interferon in an amount effective to inhibit, prevent, or control bone loss, in combination with calcitonin in an amount sufficient to inhibit, prevent, or control bone loss.

References Cited (Backward Citations)

DE3436638A1 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1993-04-30 1993-10-30 1994-05-01 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1997-04-30 1997-10-30 1998-05-01 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2001-04-30 2001-10-30 2002-05-01 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag